Results 41 to 50 of about 7,522 (217)
Photodiagnosis and Photodynamic TherapyObjective: Photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT) is effective for preventing recurrence in patients with non-muscle invasive bladder cancer (NMIBC).
Taikei Akiyama +6 more
doaj +1 more source
En Bloc Resection of Bladder Tumor—Is It the Way Forward?
Frontiers in Surgery, 2021 Transurethral resection of bladder tumors (TURBT) represents the cornerstone in diagnosis and treatment of bladder cancer but recurrence is observed in up to 80% and over- or understaging with TURBT is common.
Christian Daniel Fankhauser +4 more
doaj +1 more source
Advanced Science, EarlyView.Routine serial H&E specimens from bladder cancer are converted into paired T0/T1 digital pathology readouts of tumor evolution. Progression is associated with longitudinal nuclear drift, with nuclear size‐related changes most evident in the independent confirmation cohort, alongside a broader spatial burden of increased nuclear area and biological ...
Xing Liu +14 more
wiley +1 more source
Utility of restage transurethral resection of bladder tumor
Indian Journal of Urology, 2018 Introduction: Transurethral resection of bladder tumor (TURBT) aims at complete resection of all the visible tumors. Existing guidelines recommend restage TURBT in all patients with T1 and high-grade tumors, to avoid under-staging. However, restage TURBT
Vignesh Manoharan +7 more
doaj +1 more source
Annals of Urologic Oncology, 2020 Objective The primary aim of the study was to study the histological changes (Thermal artefacts) noted in the resected specimens between the Monopolar and Bipolar Trans-Urethral Resection of Bladder Tumours (TURBT).
Vasudevan Thirugnanasambandam, Jeyaraman Ramanathan
doaj +1 more source
Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. [PDF]
PLoS ONE, 2017 The prognostic value of repeat transurethral resection of bladder tumor (TURBT) in patients with diagnosed high-risk, non-muscle-invasive bladder cancer (NMIBC) was investigated.
Bum Sik Tae +5 more
doaj +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
陆军军医大学学报Objective To investigate risk factors for residual lesions after initial transurethral resection of bladder tumors (TURBT) and risk factors for tumor recurrence after second TURBT in patients with non-muscle-invasive bladder cancer (NMIBC) in order ...
AO Yangkun, LUO Weiming, RAN Qiang
doaj +1 more source
Frontiers in Surgery, 2023 Bladder cancer is the most common malignant tumor of urinary system worldwide. Approximately 75% of patients with bladder cancer present with non-muscle-invasive bladder cancer (NMIBC), which is effectively managed with transurethral resection of bladder
Xinghui Sun, Tianzeng Dai, Lihui Xu
doaj +1 more source
Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer
Asia-Pacific Journal of Clinical Oncology, EarlyView.Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne +6 more
wiley +1 more source